Moonlighter 2: The Endless Vault Launches in Early Access
11 Bit Studios and developer Digital Sun have released their dungeon-crawler action game Moonlighter 2: The Endless Vault in Early Access on Steam and PC Game Pass.
What’s in the Moonlighter 2: The Endless Vault Early Access?
The game launches in Early Access with a solid chunk of content that gives players a clear idea of what Digital Sun is currently building.
The Moonlighter 2 early access will feature:
3 dimensions (3 biomes)
4 combat styles (spear, sword, greatsword, fists)
50+ enemy types
160+ relics to loot
Customizable and functioning shop gameplay
Close to 100 shop and dungeon perks
Digital Sun didn’t provide an Early Access end date as they will fully release it “when they think it’s ready”, but they outlined the content they’re planning for the full version:
Additional environments
More enemies, bosses, and loot
Expanded shop systems, events, and customization
New NPCs, quests, and story moments
UI and quality-of-life improvements based on feedback
Moonlighter 2: The Endless Vault is a dungeon crawler where you dive into dungeons at night to gather relics and treasures. By day, you sell your finds in your own shop, helping grow your business and your capabilities as an adventurer. It keeps the shopkeeper-meets-dungeon-delver formula from the first game, similar in spirit to what Dave the Diver does with its split gameplay loop.
On Steam, Early Access is priced at ₱910 (USD $24) and is 17% off until December 4. The game is also available via PC Game Pass.
About the Author - Carlos Hernandez
Carlos Hernandez is the founder and Editor-in-Chief of Too Much Gaming, where he writes about video games, reviews, and industry news. A lifelong gamer, he would do anything to experience Final Fantasy Tactics for the first time again and has a love/hate relationship with games that require hunting for new gear to improve your character.
Marathon is Bungie's ambitious extraction shooter set in the world of the classic trilogy. With over 100 hours played, here's our full review of what works, what doesn't, and who it's really for.